In the second episode of this podcast series, Dr Malone, Dr Gómez-Lumbreras, and host, Dr Burger, will discuss the drug-drug interaction potential of colchicine, which may be underestimated.

Dr. Malone’s research group did a study on real-world data on the interaction potential of colchicine. Colchicine concentration can be increased by CYP3A4 inhibitors, which may lead to toxicity and adverse events. Adverse events cases reported between 2004 and 2020 were studied for the involvement of colchicine in DDIs. In 66% of 787 studied reports, colchicine was identified as a concomitant drug. This indicates that the reporter did not think colchicine was the cause of the adverse events mentioned in the reports.

• Could colchicine possibly play a bigger role in DDIs than currently thought?
• Are there any safety concerns of colchicine use combined with strong CYP3A4 inhibitors?
• And what practical guidance is needed for the safe use of colchicine in combination with other medicines?

Listen to the second episode of DDI of the Month to find out! - the episode is live

Access all episodes here: https://academicmedicaleducation.com/ddi-month-podcast

Go to the DDI Managers to utilize the online resources designed to assist healthcare professionals in prescribing and enhancing overall quality of life for their patients. You can access a DDI manager for a specific disease and search for the related drugs from there.